SOURCE: Equity Markets Inc

September 22, 2011 09:00 ET

Global Situation & Resulting Influences - Research Report on Celgene Corporation and Cell Therapeutics, Inc.

MACAU--(Marketwire - Sep 22, 2011) - Today, announced its research report highlighting Celgene Corporation (NASDAQ: CELG) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Full content and research is available at

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments" weary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed Celgene Corporation for its current position within the healthcare industry. Celgene Corporation is a global integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases, such as immunomodulation and intracellular signaling pathways in hematology, oncology and immune-inflammatory diseases. The full research report on Celgene Corporation (NASDAQ: CELG) is available here:

Equity Markets has reviewed Cell Therapeutics, Inc. for its development within the healthcare industry. Cell Therapeutics, Inc. (CTI) develops, acquires and commercializes treatments for cancer. CTI is focused on the development, acquisition and commercialization of treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. The full research report on Cell Therapeutics, Inc. (NASDAQ: CTIC) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information